Back to top
more

Better trading starts here.

Brokerage Reports

Research for LCTX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

Lineage Cell Therapeutics, Inc. [LCTX]

Reports for Purchase

Showing records 81 - 99 ( 99 total )

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 81

05/12/2020

Company Report

Pages: 7

BUY- OpGen Clinical Data

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 82

05/08/2020

Company Report

Pages: 6

1Q20 Results: Cranking on All Pistons With More to Come

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 83

05/07/2020

Daily Note

Pages: 4

Busy Bees at Lineage Cell; VAC2 Option Exercised From CRUK Based on Immunogenicity Data

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 84

05/06/2020

Company Report

Pages: 7

ARVO OpRegen Update Keep Things Nicely on Track

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 85

05/05/2020

Company Report

Pages: 7

Straight to the Dendritic Cell Workhorse for COVID-19; Approach Makes Sense to Us

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 86

05/05/2020

Company Report

Pages: 9

BUY: SARS-CoV-2 Vaccine - Maybe with CIRM

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 87

03/13/2020

Company Report

Pages: 7

2019 Results; Marching Towards Key Updates Through 2020 Beginning With Dry-AMD in Early May

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 88

02/11/2020

Company Report

Pages: 9

Is the Market Seeing the Potential in AMD?

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 89

02/06/2020

Company Report

Pages: 9

All Signs Suggest Positive Progress in AMD

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 90

02/06/2020

Daily Note

Pages: 4

Checking off Important Boxes for OpRegen Program; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 91

01/09/2020

Company Report

Pages: 9

Good Data Continues to be Visualized

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 92

01/03/2020

Company Report

Pages: 6

Starting 2020 With Positive Updates and Cash Infusion

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 93

11/18/2019

Company Report

Pages: 8

KOLs Add Fuel to Our Lineage Investment Case

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 94

11/13/2019

Company Report

Pages: 7

3Q19 Results; Continued Eyes on OpRegen Plus Pipeline Visibility in 2020; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 95

10/15/2019

Company Report

Pages: 6

Positive OpRegen Clinical Update and Durability Case Continues to Build; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 96

10/15/2019

Company Report

Pages: 9

Positive Update from AAO

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 97

09/19/2019

Company Report

Pages: 7

Renevia Awarded CE Mark in E.U.; Important Validation for Rebranded Lineage

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 98

09/19/2019

Company Report

Pages: 9

Proof of Concept - Check That Box

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 99

08/12/2019

Company Report

Pages: 9

BioTime More Than Just a Name Change

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party